Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
9h
GlobalData on MSNSanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Hugo Ricardo Huacuz was one of the top leaders of the Taney County Health Department. He pleaded guilty to wire fraud, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results